Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study

John M S Bartlett; Kenneth J Bloom; Tammy Piper; Thomas J Lawton; Cornelis J H van de Velde; Douglas T Ross; Brian Z Ring; Robert S Seitz; Rodney A Beck; Annette Hasenburg; Dirk Kieback; Hein Putter; Christos Markopoulos; Luc Dirix; Caroline Seynaeve; Daniel Rea

doi:10.1200/JCO.2012.42.8896

Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study

John M S Bartlett, Kenneth J Bloom, Tammy Piper, Thomas J Lawton, Cornelis J H van de Velde, Douglas T Ross, Brian Z Ring, Robert S Seitz, Rodney A Beck, Annette Hasenburg, Dirk Kieback, Hein Putter, Christos Markopoulos, Luc Dirix, Caroline Seynaeve, Daniel Rea

Cancer Clinical Trials Unit

Research output: Contribution to journal › Article › peer-review

42 Citations (Scopus)

Abstract

Some postmenopausal patients with hormone-sensitive early breast cancer remain at high risk of relapse despite endocrine therapy and, in addition, might benefit from adjuvant chemotherapy. The challenge is to prospectively identify such patients. The Mammostrat test uses five immunohistochemical markers to stratify patients regarding recurrence risk and may inform treatment decisions. We tested the efficacy of this panel in the Tamoxifen versus Exemestane Adjuvant Multicenter (TEAM) trial.

Original language	English
Pages (from-to)	4477-84
Number of pages	8
Journal	Journal of Clinical Oncology
Volume	30
Issue number	36
DOIs	https://doi.org/10.1200/JCO.2012.42.8896
Publication status	Published - 20 Dec 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.2012.42.8896

Cite this

Bartlett, J. M. S., Bloom, K. J., Piper, T., Lawton, T. J., van de Velde, C. J. H., Ross, D. T., Ring, B. Z., Seitz, R. S., Beck, R. A., Hasenburg, A., Kieback, D., Putter, H., Markopoulos, C., Dirix, L., Seynaeve, C., & Rea, D. (2012). Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study. Journal of Clinical Oncology , 30(36), 4477-84. https://doi.org/10.1200/JCO.2012.42.8896

@article{c2e505f3f4b143368d101a6cd9cb791d,

title = "Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study",

abstract = "Some postmenopausal patients with hormone-sensitive early breast cancer remain at high risk of relapse despite endocrine therapy and, in addition, might benefit from adjuvant chemotherapy. The challenge is to prospectively identify such patients. The Mammostrat test uses five immunohistochemical markers to stratify patients regarding recurrence risk and may inform treatment decisions. We tested the efficacy of this panel in the Tamoxifen versus Exemestane Adjuvant Multicenter (TEAM) trial.",

author = "Bartlett, {John M S} and Bloom, {Kenneth J} and Tammy Piper and Lawton, {Thomas J} and {van de Velde}, {Cornelis J H} and Ross, {Douglas T} and Ring, {Brian Z} and Seitz, {Robert S} and Beck, {Rodney A} and Annette Hasenburg and Dirk Kieback and Hein Putter and Christos Markopoulos and Luc Dirix and Caroline Seynaeve and Daniel Rea",

year = "2012",

month = dec,

day = "20",

doi = "10.1200/JCO.2012.42.8896",

language = "English",

volume = "30",

pages = "4477--84",

journal = "Journal of Clinical Oncology ",

issn = "1527-7755",

publisher = "American Society of Clinical Oncology",

number = "36",

}

Bartlett, JMS, Bloom, KJ, Piper, T, Lawton, TJ, van de Velde, CJH, Ross, DT, Ring, BZ, Seitz, RS, Beck, RA, Hasenburg, A, Kieback, D, Putter, H, Markopoulos, C, Dirix, L, Seynaeve, C & Rea, D 2012, 'Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study', Journal of Clinical Oncology , vol. 30, no. 36, pp. 4477-84. https://doi.org/10.1200/JCO.2012.42.8896

Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study. / Bartlett, John M S; Bloom, Kenneth J; Piper, Tammy et al.
In: Journal of Clinical Oncology , Vol. 30, No. 36, 20.12.2012, p. 4477-84.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study

AU - Bartlett, John M S

AU - Bloom, Kenneth J

AU - Piper, Tammy

AU - Lawton, Thomas J

AU - van de Velde, Cornelis J H

AU - Ross, Douglas T

AU - Ring, Brian Z

AU - Seitz, Robert S

AU - Beck, Rodney A

AU - Hasenburg, Annette

AU - Kieback, Dirk

AU - Putter, Hein

AU - Markopoulos, Christos

AU - Dirix, Luc

AU - Seynaeve, Caroline

AU - Rea, Daniel

PY - 2012/12/20

Y1 - 2012/12/20

N2 - Some postmenopausal patients with hormone-sensitive early breast cancer remain at high risk of relapse despite endocrine therapy and, in addition, might benefit from adjuvant chemotherapy. The challenge is to prospectively identify such patients. The Mammostrat test uses five immunohistochemical markers to stratify patients regarding recurrence risk and may inform treatment decisions. We tested the efficacy of this panel in the Tamoxifen versus Exemestane Adjuvant Multicenter (TEAM) trial.

AB - Some postmenopausal patients with hormone-sensitive early breast cancer remain at high risk of relapse despite endocrine therapy and, in addition, might benefit from adjuvant chemotherapy. The challenge is to prospectively identify such patients. The Mammostrat test uses five immunohistochemical markers to stratify patients regarding recurrence risk and may inform treatment decisions. We tested the efficacy of this panel in the Tamoxifen versus Exemestane Adjuvant Multicenter (TEAM) trial.

U2 - 10.1200/JCO.2012.42.8896

DO - 10.1200/JCO.2012.42.8896

M3 - Article

C2 - 23045591

SN - 1527-7755

VL - 30

SP - 4477

EP - 4484

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 36

ER -

Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this